Paul, happily, our "thread" is occupied by both "gnomes" (i.e., fundamentalists) and "elves" (i.e., technicians). You have the distinction of being our "chief elf" (to use Louis Ruckeyser's term). And I'm sorry that us gnomes monopolized the board yesterday; the elves couldn't get a word in edgewise! Two things about your note: 1) even though PRLN's herbs have a long history of use in TCM, they might have to be used at higher concentrations or more frequently when used to attack AIDS or cancer. Thus, their toxicology profile must be determined anew for such higher concentrations/frequency of use. 2) the preliminary results for six patients that PRLN released awhile back were cancer patients using PN 27,1--we were more concerned about getting preliminary results on PN355. Finally, I've attached a previous newswire release from PRLN. It might help to explain why we're not getting early release of their Phase 1 trials with PN355. My guess is that PRLN may want Babish to release outcome results during his presentation at the big HIV/AIDS conference scheduled for November. The other piece of valuable information that the article contained, in my opinion, was a listing of other companies engaged in their own research programs involving HIV/AIDS.
""06/10 Paracelsian Invited To Participated In AIDS Conference
ITHACA, N.Y.--(BUSINESS WIRE)--June 10, 1996--John G. Babish, Ph.D., vice
president and chief science officer of Paracelsian, Inc. (NASDAQ:PRLN) has
been invited to speak at the Novel HIV Therapeutic Strategies Conference,
scheduled to take place in McLean Va., Nov. 20-21, 1996.
The conference is sponsored by the Cambridge Healthtech Institute and is
expected to bring together noted AIDS researchers from throughout the world.
Dr. Babish will address "Clinical studies on a novel kinase inhibitor PN 355
for the treatment of HIV and cancer." It is expected that his presentation
will focus on the results to date of Paracelsian's testing of its anti-HIV
compound, PN 355, which is presently in clinical trials at Bastyr University,
in Seattle, Wash.
The conference will address a number of topics as they relate to new ways in
which to treat HIV/AIDS. Already conference organizers have confirmed that in
addition to Paracelsian, speakers from Merck Research Labs, RiboGene,
University of Pennsylvania, Trimeris, Cell Genesys, Stanford University,
National Cancer Institute, Boston University, Receptagen, Immune Response
Corp., and the University of Pittsburgh Medical Center have accepted
invitations to participate.
Presentations will be made in three areas: Novel Targets for Viral
Replication and Infectivity; Immunological Enhancement and Protection of
Immune Cells.
Paracelsian is a biotech company engaged in the discovery of pharmaceuticals
from herbal sources and the development and marketing of tests for improved
cancer diagnosis and environmental carcinogens, utilizing the proprietary
technology of the company. In addition to its clinical trials for PN 355 at
Bastyr University, the company recently expanded its compassionate use trials
for its anti-cancer compound, PN 27, 1, which has been found to have activity
against prostate and breast cancers and non-Hodgkin's lymphomas.
CONTACT: Arthur A. Koch, Jr., 607/257-4224
Bev Jedynak, 312/943-1100
|
